1 Vitamin D and Covid-19 Susceptibility and Severity: a Mendelian Randomization 2 Study

2 **S** 3

9

13

14

20

21

22

23

24

25

26

27

4 Authors:

*Guillaume Butler-Laporte^{1,2}, *Tomoko Nakanishi^{1,3,4,5}, Vincent Mooser^{3,6}, David R.
Morrison¹, Tala Abdullah¹, Olumide Adeleye¹, Noor Mamlouk¹, Nofar Kimchi^{1,7}, Zaman Afrasiabi¹, Nardin Rezk¹, Annarita Giliberti⁸, Alessandra Renieri^{8,9}, Yiheng Chen¹, Sirui Zhou^{1,2}, Vincenzo Forgetta¹, J Brent Richards^{1,2,3,10}

10 *These authors made equal contributions to this manuscript.

1112 Affiliations:

- 1) Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada
- Department of Epidemiology, Biostatistics and Occupational Health, McGill
 University, Montréal, Québec, Canada
 - University, Montréal, Québec, Canada 3) Department of Human Genetics, McGill University Montréal, Québec, Canada
- Department of Human Genetics, McGill University Montréal, Québec, Canada
 Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate
 School of Medicine, Kyoto University, Kyoto, Japan
 - 5) Research Fellow, Japan Society for the Promotion of Science
 - 6) Canada Excellence Research Chair in Genomic Medicine, McGill University, Montréal, Québec, Canada
 - 7) Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Israel
 - 8) Medical Genetics, University of Siena, Siena, Italy
 - 9) Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy
 - 10) Department of Twin Research, King's College London, London, United Kingdom

2829 Corresponding author:

- 30 Brent Richards, Professor of Medicine
- 31 McGill University
- 32 Senior Lecturer, King's College London (Honorary)
- 33 Contact:
- 34 Pavilion H-413, Jewish General Hospital
- 35 3755 Côte-Ste-Catherine
- Montréal, Québec, Canada, H3T 1E2
- 37 T: +1 514 340 8222 x24362 F: +1 514 340 7529
- 38 E: brent.richards@mcgill.ca
- 39 <u>www.mcgill.ca/genepi</u>
- 40
- 41 Funding:

The Richards research group is supported by the Canadian Institutes of Health 42 Research (CIHR: 365825: 409511), the Lady Davis Institute of the Jewish General 43 44 Hospital, the Canadian Foundation for Innovation, the NIH Foundation, Cancer 45 Research UK, Genome Québec, the Public Health Agency of Canada and the Fonds de Recherche Québec Santé (FRQS). GBL is supported by a joint scholarship from the 46 FRQS and Québec's Ministry of Health and Social Services. TN is supported by 47 48 Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young 49 Scientists and JSPS Overseas Challenge Program for Young Researchers. JBR is 50 supported by a FRQS Clinical Research Scholarship. Support from Calcul Québec and 51 Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. These funding agencies had no role in the design, implementation or interpretation of this study.

57

58 Disclosures:

JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital. These agencies had no role in the design, implementation or interpretation of this study.

61

62 Article type: Research

- 63 Word count: 3315 (Introduction, Methods, Results, and Discussion)
- 64 Key words: Vitamin D, Covid-19, Sars-CoV-2, Mendelian Randomization, Outcome
- 65 66

67 Abstract

68 Introduction

Increased vitamin D levels, as reflected by 25OHD measurements, has been proposed to protect against Covid-19 disease based on *in-vitro*, observational, and ecological studies. However, vitamin D levels are associated with many confounding variables and thus associations described to date may not be causal. Vitamin D MR studies have provided results that are concordant with large-scale vitamin D randomized trials. Here, we used two-sample MR to assess the effect of circulating 25OHD levels on Covid-19 susceptibility.

- 76
- 77 Methods

Genetic variants strongly associated with 25OHD levels in a 443,734-participant genome-wide association study (GWAS) were used as instrumental variables. GWASs of Covid-19 susceptibility and severity from the Covid-19 Host Genetics Initiative were used to test the effect of 25OHD levels on these outcomes. Cohorts from the Covid-19 Host Genetics Initiative GWAS included up to 966,395 individuals of European ancestry.

83 84 *Results*

Genetically increased 25OHD levels by one standard deviation on the logarithmic scale had no clear effect on susceptibility but tended to increase the odds ratio of hospitalization (OR = 2.34; 95% CI: 1.33, 4.11) and severe disease (OR = 2.21; 95% CI: 0.87, 5.55). Extensive sensitivity analyses probing the assumptions of MR provided consistent estimates.

90

91 Conclusion

92 These findings do not support a protective role of increased 25OHD levels on Covid-19

93 outcomes and may suggest harm. At present, individuals should not use vitamin D

supplements to protect against Covid-19 outcomes, and on-going supplementation trials

95 should closely monitor for signals of harm.

96 Introduction

SARS-CoV-2 infection has killed hundreds of thousands of individuals and has led to the
largest economic contraction since the Great Depression¹. Vaccines are many months
away and their resultant immunity is unknown². Therefore, therapies are required to treat
severe Covid-19 disease and to prevent its complications. Therapeutic development, in
turn, requires well-validated drug targets to lessen Covid-19 severity.

102

103 Recently, vitamin D status, as reflected by 25-hydroxy-vitamin D (25OHD) level has 104 been identified potentially actionable drug target in the prevention and treatment of Covid-19³. As the pre-hormone to the biologically active calcitriol, 250HD has been 105 epidemiologically linked to many health outcomes^{4,5}. Given calcitriol's recognized in-vitro 106 immunomodulatory role⁶, as well as observational and ecological studies on measured 107 25OHD blood levels and Covid-19^{7,8}, the vitamin D pathway might be a biologically 108 plausible target in Covid-19. This could be of public health importance, given that the 109 prevalence of vitamin D insufficiency is high in most countries, and that more than 37% 110 111 of elderly adults in the USA take vitamin D supplements⁹. Further, 25OHD 112 supplementation is inexpensive and reasonably safe—thus providing a potential avenue 113 to lessen the burden of the SARS-CoV-2 pandemic.

114

115 However, observational studies on 25OHD are prone to confounding and reverse 116 causation bias. Confounding happens when the relationship between exposure (25OHD) and the outcome (Covid-19) is influenced by an unobserved, or improperly controlled 117 118 common causes. Reverse causation happens when the outcome itself is a cause of the 119 exposure. Likewise, conclusions drawn from *in-vitro* may not be applicable *in-vivo*. 120 Accordingly, randomized controlled trials (RCTs) on 250HD supplementation have been 121 undertaken to test their effect on disease outcomes where observational studies have supported a role for 25OHD level. However, across endocrinology, respirology, 122 cardiology, and other specialties, these trials have most often have failed to show clinical 123 benefits^{10–12}. Some RCTs have even shown detriment to 25OHD supplementation¹³. In 124 the field of infectious diseases, a trial of 25OHD supplementation showed increased risk 125 126 of upper respiratory infection in the intervention arm¹⁴, and a recent trial on sepsis obtained a numerically higher mortality rate in patients who received 25OHD 127 supplementation¹⁵. However, while RCTs can control for confounding and provide 128 129 unbiased estimates of the effect of 25OHD supplementation in Covid-19, they require considerable time, as well as financial and human resources. 130

131

Presently, there are more than 15 registered on-going RCTs testing the effect of vitamin D on Covid-19 outcomes on clinicaltrials.gov. Given difficulties recruiting Covid-19 patients into trials and the probability that epidemiological estimates of vitamin D effects are likely to be confounded, data are urgently needed to assess the causal role of vitamin D on Covid-19 outcomes.

137

Mendelian randomization (MR) is a genetic epidemiology method that uses genetic 138 variants as instrumental variables to infer the causal effect of an exposure (in this case 139 25OHD level) on an outcome (in this case, Covid-19 susceptibility and severity)¹⁶. MR 140 overcomes confounding bias since genetic alleles are randomized to the individual at 141 142 conception, thereby breaking associations with most confounders. Similarly, since 143 genetic alleles are always assigned prior to disease onset, they are not influenced by reverse causation. In the case of vitamin D, MR has been able to provide causal effect 144 estimates consistently in line with those obtained from RCTs^{10,17-21}, and would therefore 145 support investments in 250HD supplementation trials in Covid-19, if a benefit was 146

shown. Further, since MR results can be generated rapidly, such evidence may provideinterim findings while awaiting RCT results.

149

However, MR relies on several core assumptions²². First, genetic variants must be 150 associated with the exposure of interest. Second, they should not affect the outcome 151 except through effects on the exposure (also known as lack of horizontal pleiotropy). 152 153 Third, they should not associate with the confounders of the exposure-outcome 154 relationship. Of these, the most problematic is the second assumption. Yet, in the case 155 of 25OHD, many of its genetic determinants reside at loci that harbour genes whose roles in 25OHD production, metabolism and transport are well known²³. Leveraging this 156 known physiology can help to prevent the incorporation of genetic variants that could 157 158 lead to horizontal pleiotropy.

159

Here, we used genetic determinants of serum 25OHD from a recent genome-wide association study (GWAS) and meta-analysis of more than 443,734 participants of European ancestry²⁴ in an MR study to test the effect of increased 25OHD level on Covid-19 susceptibility and severity.

164 165 **Methods**

We used a two-sample MR approach to estimate the effect of 25OHD levels on Covid-19 susceptibility and severity. In two-sample MR²⁵, the effect of genetic variants on 25OHD and on Covid-19 outcomes are estimated in separate GWASs from different populations. This allows for increased statistical power by increasing the sample size in both the exposure and outcome cohorts.

171

172 Choice of 250HD genetic instruments

To find genetic variants explaining 25OHD levels²⁴, we used a GWAS from our group, 173 which is the largest published GWAS of 25OHD levels. We selected SNPs whose effect 174 on 25OHD level was genome-wide significant (P<5x10⁻⁸), minor allele frequency was 175 more than 1%, and which were identified using conditional and joint (COJO) analysis²⁶. 176 177 COJO identifies conditionally independent SNPs and allows for the addition of more 178 genetic instruments without generating falsely narrow confidence intervals due to genetic 179 linkage disequilibrium. For SNPs that were not available in the outcome GWAS or with 180 palindromic alleles of intermediate frequency (between 42% and 58%), we used the LDlink tool²⁷ to find genetic proxies in the European 1000 Genomes dataset using 181 182 linkage disequilibrium threshold (r^2) of 90%.

183

184 Covid-19 outcome definitions and GWASs

We used the Covid-19 Host Genetics Initiative (Covid-19 HGI) phenotype definitions and GWAS summary statistics for Covid-19 susceptibility, hospitalization, and severe disease outcomes²⁸. We meta-analyzed summary statistics from cohorts of European ancestry to obtain the effects of the 25OHD-associated genetics variants on Covid-19 outcomes. Fixed effect meta-analysis models were used to combine summary statistics, with the METAL package²⁹.

191

The susceptibility phenotype compared confirmed Covid-19 cases, defined as laboratory confirmed of SARS-CoV-2 infection based on RNA or serology tests, or by electronic health records (using International Classification of Diseases or physician notes), with controls defined as laboratory tested negative for SARS-CoV-2 infection (for all tests if multiple were performed) or self-reported test negative. The hospitalized phenotype compared cases defined as hospitalized patients with Covid-19, and controls as Covid198 19 positive non-hospitalized individuals. The severe disease phenotype cases were 199 defined as hospitalized individuals with Covid-19 and requiring respiratory support. 200 Respiratory support was defined as intubation, CPAP, BiPAP, continuous external 201 negative pressure, or high flow nasal cannula. Controls were also non-hospitalized 202 Covid-19 infected individuals. Details of the three phenotypes are found in **Table 1** and 203 **Supplement 1**. Details of the UKB GWAS are found in **Supplement 2**.

204

205 Primary MR analysis

The effect of 25OHD level on Covid-19 outcomes was obtained for each SNP by using the Wald ratio method. The effect of each SNP was given in standardized logtransformed 25OHD level. Each estimate was first meta-analyzed using the IVW method, and then using MR Egger to provide an estimate of directional pleiotropic effects. Allele harmonization and computations were performed using the TwoSampleMR package³⁰.

212

213 Horizontal pleiotropy sensitivity analysis

We undertook extensive analysis to assess the risk of horizontal pleiotropy (in violation of the second MR assumption). First, we used MR Egger methods. MR Egger allows for an additional intercept (alpha) term which provides an estimate of directional horizontal pleiotropy.

218

Second, we restricted our choices of SNPs to those whose closest gene is directly involved in the Vitamin D pathway. These genes have an established role in vitamin D regulation through its synthesis (*DHCR7/NADSYN1* and *CYP2R1*), transportation (*GC*), and degradation (*CYP24A1*) (Figure 1). This decreases the risk of selecting a genetic variant that effects Covid-19 outcomes independent of their effect on 250HD levels.

224

Third, we used the Phenoscanner tool^{31,32} on the remaining SNPs to check for variants associated (at a genome-wide significant threshold of $p=5x10^{-8}$) with phenotypes at risk of affecting Covid-19 outcomes independent of 25OHD, making them at higher risk of horizontal or vertical pleiotropy. Note that vertical pleiotropy, which happens when the Covid-19 outcome is influenced by a phenotype directly in the causal pathway between 25OHD level and Covid-19 outcome, does not violate MR assumptions.

231

232 Extended Phenotypes

Finally, we also used an extended susceptibility, an extended hospitalized, and an extended severe disease phenotype whereas controls were defined as all non-cases in the included cohorts. MR analyses were performed as described above. Details of these phenotypes and the MR results are found in **Supplement 2**.

237

238 Research Ethics

Each cohort included in this study received their respective institutional research ethics
 board approval to enroll patients. All information used for this study are publicly available
 as deidentified GWAS summary statistics.

242

243 **Results**

244 Choice of 25OHD genetic instruments

We obtained our 25OHD genetic instruments from our previously published GWAS²⁴ on circulating 25OHD levels in 401,460 white British participants in the UK Biobank (UKB)³³, which was meta-analyzed with a GWAS on 25OHD levels of 42,274 participants of

European ancestry³⁴. From this, we used single nucleotide variants (SNPs) from the

conditional and joint (COJO) analysis²⁶. Of the 138 reported conditionally independent
 SNPs (explaining 4.9% of the 25OHD variance), 100 had a minor allele frequency of
 more than 1%. These explained 3.9% of the variance in 25OHD serum levels.

252

253 Covid-19 outcome definitions and GWASs

Using the Covid-19 Host Genetics Initiative (Covid-19 HGI) results restricted to cohorts of European ancestry, we used a total of 3,432 cases and 41,285 controls to define Covid-19 susceptibility, 867 cases and 2,229 controls to define Covid-19 hospitalization, and 293 cases and 607 controls to define Covid-19 severe disease. **Table 1** summarizes the definition and sample size of both the exposure and outcome GWASs. Since the UKB was used in the two phases of the MR study, some overlap between the exposure and the outcome GWASs was unavoidable (**Supplement 1**).

261

For the susceptibility and severe disease phenotypes, 98 of the 138 conditionally independent SNPs influencing 250HD level were available in the outcome GWAS. For the severe disease outcome, 97 SNPs were available in the outcome GWAS. There was a total of 4 palindromic alleles with intermediate frequencies. Genetic proxies (linkage disequilibrium $r^2 > 90\%$) found in the European sub-cohort of the 1000 Genomes dataset were also unavailable in the outcome GWAS, and no proxies were used for the analyses below. **Table 2** shows the total number of SNP instruments used for each analysis.

269

270 Primary MR analysis

271 We first used inverse-weighted variance (IVW) meta-analysis to combine effect estimates from each genetic instrument. For a standard deviation increase in log-272 273 transformed 25OHD level, we observed no clear effect upon odds of susceptibility (OR = 274 0.88; 95% CI: 0.69, 1.11; P = 0.26). However, we observed an increased risk of 275 hospitalization per standard deviation increase in log-transformed 25OHD (OR = 2.34; 276 95% CI: 1.33, 4.11; P = 0.003) and trend towards increased risk of severe disease (OR 277 = 2.21; 95% CI: 0.88, 5.55; P = 0.09) (Table 2). Figure 2 shows the result of these 278 analyses.

279

280 Horizontal pleiotropy sensitivity analysis

While MR Egger has less statistical power to detect an effect than IVW meta-analysis,
we still found similar effect estimates for increased 25OHD levels on susceptibility (OR =
0.61; 95% CI: 0.37, 1.01; P=0.7), hospitalization (OR = 1.97; 95% CI: 0.66, 5.84;
P=0.24) and severe disease (OR = 7.68; 95% CI: 1.35, 43.5; P=0.03). MR Egger did not
show evidence of directional pleiotropic effects for these analyses.

286

287 Then, we restricted SNPs which reside close to the four genes directly involved in 250HD metabolism. This left 24 SNPs, explaining 2.7% of 250HD variation. Using these 288 SNPs, each standard deviation increase in log-transformed 25OHD was not associated 289 with a clear effect on Covid-19 susceptibility (OR = 0.90; 95% CI: 0.64, 1.27; P = 0.55). 290 291 However, we again observed a trend towards increased odds of hospitalization for each 292 standard deviation increase in 25OHD levels on the logarithmic scale (OR = 2.52 [95% 293 CI: 1.28, 4.95]; P = 0.007) and severe disease (OR = 3.04; 95% CI: 1.06, 8.76; P = 0.04). For the three phenotypes, the intercept term confidence interval crossed the null, 294 295 again suggesting a lack of directional horizontal pleiotropy.

296

Lastly, we used the Phenoscanner^{31,32} tool to check if the SNPs used in the MR study were associated with other phenotypes. Using Phenoscanner, rs11723621 was associated with white blood cell level, and rs6127099 was associated with glomerular 300 filtration rate. In both cases, the effect on each phenotype was mild compared to their 301 effect on 25OHD level, as rs11723621 explained less than 0.03% of the variance in 302 white blood cell counts, and rs6127099 explained less than 0.001% of the glomerular filtration rate variance^{35,36}. Removing these SNPs from the 24 SNPs above further 303 decreased the proportion of 25OHD variance explained to 1.6%. While confidence 304 intervals widened, effect estimates when restricting our analysis to these 22 SNPs 305 306 remained similar for susceptibility (0.77; 95% CI: 0.48, 1.23; P=0.27), hospitalization 307 (2.89; 95% CI: 1.18, 7.06; P=0.02), and severe disease (2.52; 95% CI: 0.63, 10.0; 308 P=0.19).

309

310 Extended Phenotypes

311 Next, we used an extended definition for all three outcomes, where controls were 312 defined as all non-cases in each cohort, regardless of whether the Covid-19 status was known or not. For these we obtained 6,182 cases and 960,186 controls for the extended 313 314 susceptibility phenotype, 2.710 cases and 813.234 controls for the extended 315 hospitalization phenotype, and 540 cases and 366,840 controls for the extended severe disease phenotype. MR analysis using the extended phenotypes showed similar results 316 317 for Covid-19 susceptibility (Supplement 2), but their confidence intervals and effect estimates were closer to the null in the extended hospitalization phenotype. For 318 319 example, for the analysis restricted to genes directly involved in vitamin D metabolism, 320 we obtained a much smaller OR (1.08; 95% CI: 0.69, 1.69; P = 0.74). However, the three extended severe disease analyses showed worse outcome with increasing 25OHD 321 322 levels.

323

324 Discussion

325 In this large-scale MR study, we found that genetically increased 25OHD levels did not 326 protect against Covid-19 susceptibility, or severity, and in some analyses was 327 associated with worsened outcomes. These findings therefore do not support vitamin D supplementation to prevent Covid-19 outcomes. These results provide guidance on the 328 329 use of vitamin D supplementation, given that a large proportion of the elderly population 330 currently takes vitamin D supplements. Further, these results should inform the design of 331 vitamin D supplementation trials, which should include attempt to identify signals of harm 332 in interim analyses.

333

These results are not consistent with those reported in observational studies on vitamin 334 335 D and Covid-19 outcomes. The discrepancy between our results and traditional 336 epidemiological studies on Covid-19 and 25OHD can likely be explained by the fact that 250HD is a highly confounded variable. It is consistently associated with an older, more 337 338 vulnerable, and more socially isolated population, all strong determinants of Covid-19 disease susceptibility and severity. Therefore, even when using advanced statistical 339 adjustments, observational epidemiological studies will likely obtain biased estimates of 340 341 the effect of vitamin D on Covid-19 in favor of increased 25OHD level. These same 342 limitations may explain the discrepancy between 25OHD observational epidemiology 343 outcomes and RCTs of vitamin D supplementation for common diseases, such as coronary heart disease, cancer, fracture and type 2 diabetes. Further, while vitamin D 344 deficiency has been associated with enhanced inflammation and cytokine release³⁷, the 345 346 concept of "cytokine storm" in sepsis is poorly defined, and is currently being reconsidered, including in the case of Covid-19³⁸. 347

348

Most importantly, 25OHD MR studies have given results consistent with RCTs in the colorectal cancer^{10,12,19}, diabetes^{11,18}, bone density and fractures^{20,39,40}, coronary artery disease^{10,21}, and many other health outcomes. Our study would also be consistent with a 2015 RCT on 25OHD supplementation in the prevention of respiratory tract infection⁷, which showed more upper respiratory tract infections and longer duration of symptoms in those randomized to 25OHD supplements. While this RCT was not powered for more severe outcomes and may not apply to the case of the Covid-19 pandemic, this further highlights the potential role of MR studies to guide future 25OHD supplementation trials.

357

358 To date, there are more than 15 trials registered on clinicaltrials.gov assessing the role 359 of 25OHD supplementation in Covid-19, with a wide variety of study designs and primary outcomes. The two largest RCTs are both placebo-controlled trial but have not yet 360 started recruitment. The first will be trial of a 2,414 participants, for which supplementation will be given to healthy Canadian healthcare workers⁴¹, while the 361 362 second is planned for 1,265 participants in Argentina admitted for Covid-19, but who 363 have not yet developed severe disease⁴². The two trials' primary outcome therefore 364 corresponds to our susceptibility and severe disease phenotypes, and our results should 365 be able to better inform their design and ensure their participants' safety. 366

367

Our findings also have important implication for large proportion of the elderly population who are already taking 25OHD supplements⁹. As the evidence for 25OHD supplementation is growing weaker for many other diseases, and with potential adverse events during the Covid-19 pandemic, official public health recommendations should be adjusted to discourage liberal use of 25OHD supplements to protect against Covid-19 outcomes.

374

375 Our study has limitations. First, we obtained discrepant results in the hospitalization and 376 extended hospitalization phenotypes. That is, the extended hospitalization MRs did not 377 show any increased risk from a genetically higher 25OHD level. However, hospitalization 378 is a "softer", more subjective outcome than severe disease, and we expect large 379 variations in hospitalization criteria between cohorts, given differences in admission 380 criteria by country. Further, by extending the hospitalization control definition to all 381 individuals without a record of Covid-19 (including those who did not have a test or whose result is unavailable), we expect that the cohorts included in the extended 382 383 hospitalization phenotype were even more heterogeneous. Hence, the extended 384 hospitalization phenotype results were likely biased towards the null. Nevertheless, our results did not show any benefit from increasing 25OHD levels, and our concerns about 385 386 vitamin D supplementation remain valid for severe disease outcomes. Second, the UKB 387 was the largest case contributor in the hospitalization phenotype, and the only 388 contributor of the severe disease phenotype. Therefore, for these phenotypes, our MR 389 analyses were closer to one-sample MRs. This distinction is important in analyses suffering from weaker genetic instruments, as the estimate will be biased. In two-sample 390 MR, this bias is towards the null hypothesis. However, in one-sample MR, the bias is in 391 the direction of the epidemiologic association²⁵. Yet, 392 univariate epidemiological 393 association studies between 25OHD and Covid-19 severe disease have demonstrated a slight benefit to higher 250HD levels in the UKB cohort^{43,44}. Therefore, if the one-sample 394 MR design introduced any bias, it would be to pull our results closer towards the 395 beneficial effects. Nevertheless, in the extended severe disease phenotype, which 396 397 incorporated data from an additional cohort with 327 cases, and the results were similar 398 to the severe disease phenotype from UKB with a severe disease odds ratio of 2.39 399 (95% Cl: 1.15, 4.96; P = 0.02) for every standard deviation increase in log transformed 400 250HD (for the analysis restricted to genes directly involved in the 250HD metabolism). 401

402 Third, we were only able to include individuals of European ancestry, and it remains possible that 25OHD levels might have different effects on Covid-19 outcomes in other 403 404 populations. However, previous RCTs on vitamin D supplementation have given similar results in populations of various ancestries^{39,40}. Our study did not consider frank vitamin 405 D deficiency, and it remains possible that vitamin D supplementation may remain 406 beneficial in this population. Nevertheless, most proposed RCTs of vitamin D 407 408 supplementation for Covid-19 (including the largest two) do not target deficient populations^{41,42}. Lastly, while we performed multiple sensitivity analyses to attempt to 409 detect horizontal pleiotropy, this source of potential bias cannot be entirely excluded. 410

411

In conclusion, using a method that has consistently replicated RCT results for 25OHD outcomes in large sample sizes, we find no evidence to support a protective role for vitamin D supplementation in Covid-19 outcomes. Our findings also suggest that all ongoing RCTs studying vitamin D supplementation should have mechanisms in place to detect early signs of worsened outcomes, and that public health recommendations should advise more caution about taking 25OHD supplements.

418

419 Acknowledgement

420 We thank the patients and investigators who contributed to the Covid-19 HGI 421 (Supplement 4) and the Vitamin D GWAS consortium. Members of the GEN-COVID 422 study are acknowledged in Supplement 5.

423 424 **Contributions**

Conception and design: GBL, TN, JBR. Data acquisition and standardization: AR, AG, 425 426 DRM, TA, OA, NM, NK, ZA. Data analyses: GBL and TN. Interpretation: GBL, TN, VM, 427 DRM, TA, OA, NM, NK, ZA, AR, AG, SZ, YC, VF, JBR. Computational resources and support: VF, JBR. Writing original draft: GBL, TN, JBR. All authors were involved in 428 429 reviewing the manuscript and critically reviewed its content. All authors gave final approval of the version to be published. The corresponding author attests that all listed 430 431 authors meet authorship criteria and that no others meeting the criteria have been 432 omitted.

433

434 Data availability

435 Covid-19 outcome GWAS summary statistics are freely available for download through 436 the Covid-19 HGI website (<u>https://www.covid19hg.org/</u>).

437

438 Funding source: The Richards research group is supported by the Canadian Institutes 439 of Health Research (CIHR), the Lady Davis Institute of the Jewish General Hospital, the 440 Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK and the Fonds de Recherche Québec Santé (FRQS). TN is supported by Research Fellowships 441 of Japan Society for the Promotion of Science (JSPS) for Young Scientists and JSPS 442 Overseas Challenge Program for Young Researchers. JBR is supported by a FRQS 443 444 Clinical Research Scholarship. TwinsUK is funded by the Wellcome Trust, Medical 445 Research Council, European Union, the National Institute for Health Research (NIHR)funded BioResource, Clinical Research Facility and Biomedical Research Centre based 446 at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College 447 448 London. These funding agencies had no role in the design, implementation or 449 interpretation of this study. This research has been conducted using the UK Biobank 450 Resource (project number: 27449).

451

452 **Competing interests:** JBR has served as an advisor to GlaxoSmithKline and Deerfield 453 Capital. These companies had no role in the design, implementation or interpretation of 454 this study.

455

Transparency statement: The manuscript's guarantors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

460

461 **Supplementary files captions**

462 **Supplement 1**: Cohorts used for each outcome phenotype for the Covid-19 Host 463 Genetics Initiative.

Supplement 2: Genome-wide association studies for the susceptibility and the severity
 of SARS-CoV-2 infections in UK Biobank.

466 **Supplement 3**: Extended phenotypes definitions and MR results.

467 **Supplement 4**: Acknowledgement to data contributors and the Covid-19 Host Genetics 468 Initiative.

469 **Supplement 5**: GEN-COVID Multicenter Study

470

 McKee, M. & Stuckler, D. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. <i>Nat. Med.</i> 26, 640–642 (2020). Koirala, A., Joo, Y. J., Khatami, A., Chiu, C. & Britton, P. N. Vaccines for COVID-19: The current state of play. <i>Paediatr. Respir. Rev.</i> (2020) doi:10.1016/j.prrv.2020.06.010. Mansur, J. L. <i>et al.</i> Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. <i>Clin. e Investig. en Arterioscler. Publ. Of. Ia Soc. Esp. Arterioscler.</i> (2020) doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Fraitty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Matrineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D Supplements Daily. 1999-2014. <i>JAMA</i> 317, 2448–2450 (2017). Roney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448–2450 (2017). Maschwiende, J. <i>et al.</i> 21, <i>J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Mactawski-Wende, J. <i>et al.</i> 21, <i>Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Calcium plus	471	Refer	ences
 damage health not just now but also in the future. <i>Nat. Med.</i> 26, 640–642 (2020). Koirala, A., Joo, Y. J., Khatami, A., Chiu, C. & Britton, P. N. Vaccines for COVID- 19: The current state of play. <i>Paediatr. Respir. Rev.</i> (2020) doi:10.1016/j.prv.2020.06.010. Mansur, J. L. <i>et al.</i> Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. <i>Clin. e Investig. en Arterioscler. Publ. Of. Ia Soc. Esp. Arterioscler.</i> (2020) doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8657(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 360, 3–44 (2019). Hettas, A. <i>et al.</i> Annual High-Dose Vitamin D and Frais and Fractures in Older Women: A Randomized Controlled Trail. <i>JAMA</i> 301, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trails and Fractures in Older Women: A Randomized Controlled Trail. <i>JAMA</i> 303, 1815–1822	472	1.	McKee, M. & Stuckler, D. If the world fails to protect the economy, COVID-19 will
 Koirala, A., Joo, Y. J., Khatami, A., Chiu, C. & Britton, P. N. Vaccines for COVID- 19: The current state of play. <i>Paediatr. Respir. Rev.</i> (2020) doi:10.1016/j.prrv.2020.06.010. Mansur, J. L. <i>et al.</i> Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. <i>Clin. e Investig. en Arterioscler. Publ. Of. Ia Soc. Esp. Arterioscler.</i> (2020) doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Vitorol.</i> (2020) doi:10.10102/jmv.26360. Rooney, M. R. <i>et al.</i> Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pitas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D Deficient Patients. <i>N. Engl. J. Med.</i> 381, 5229–2540 (2015). Ginde, A. A. <i>et al.</i> Engl. J. Med. 381, 2529–2540 (2015)	473		damage health not just now but also in the future. Nat. Med. 26, 640–642 (2020).
 475 19: The current state of play. <i>Paediatr. Respir. Rev.</i> (2020) doi:10.1016/j.prrv.2020.06.010. 476 Mansur, J. L. <i>et al.</i> Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. <i>Clin. e Investig. en</i> <i>Arterioscler. Publ. Of. Ia Soc. Esp. Arterioscler.</i> (2020) doi:10.1016/j.arteri.2020.05.003. 41 Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). 42 Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). 43 Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). 44 Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. 45 Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1006/S2213-8587(20)30268-0. 46 Munshi, R. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). 47 Pittas, A. G. <i>et al.</i> Vitamin D Supplements and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). 48 Wactawski-Wende, J. <i>et al.</i> 21, <i>J. Med.</i> 384, 684–696 (2006). 49 Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). 41 Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D. Deficient Patients. <i>N. Engl. J. Med.</i> 384, 5629–2540 (2015). 42 Sanders, K. M. <i>et al.</i> Annual High-Dose Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010).	474	2.	Koirala, A., Joo, Y. J., Khatami, A., Chiu, C. & Britton, P. N. Vaccines for COVID-
 doi:10.1016/i.prtv.2020.06.010. Mansur, J. L. <i>et al.</i> Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. <i>Clin. e Investig. en Arterioscler. Publ. Of. Ia Soc. Esp. Arterioscler.</i> (2020) doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Fraitly Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 360, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 360, 33–44 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older a	475		19: The current state of play. Paediatr. Respir. Rev. (2020)
 Mansur, J. L. <i>et al.</i> Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. <i>Clin. e Investig. en Arterioscler. Publ. Of. Ia Soc. Esp. Arterioscler.</i> (2020) doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448- 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 350, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin	476		doi:10.1016/j.prrv.2020.06.010.
 promising alternative to prevent or treat COVID-19 infection. <i>Clin. e Investig. en</i> <i>Arterioscler. Publ. Of. Ia Soc. Esp. Arterioscler.</i> (2020) doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D : A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martois-Pérez, D. <i>et al.</i> Low Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8687(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (VIDFIL). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D (3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Ye, Z. <i></i>	477	3.	Mansur, J. L. et al. Vitamin D high doses supplementation could represent a
 Arterioscler. Publ. Of. la Soc. Esp. Arterioscler. (2020) doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. Nutrients 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. Nutrients 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. Adv. Exp. Med. Biol. 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol. (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J. Med. Virol. (2020) doi:10.1002/mv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. JAMA 317, 2448- 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 381, 520–530 (2019). Sanders, K. M. <i>et al.</i> Annual High-Dose Ortal Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-bilind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Entyl High-Dose Vitamin D (3) for Critically III, Vitamin D- Deficient Patients. N. Engl. J. Med. 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018). <l< td=""><td>478</td><td></td><td>promising alternative to prevent or treat COVID-19 infection. Clin. e Investig. en</td></l<>	478		promising alternative to prevent or treat COVID-19 infection. Clin. e Investig. en
 doi:10.1016/j.arteri.2020.05.003. Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A R andomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carres (ViDFIU). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian r	479		Arterioscler. Publ. Of. la Soc. Esp. Arterioscler. (2020)
 Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.10016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplements and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Duble-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Engl. <i>J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018).<td>480</td><td></td><td>doi:10.1016/j.arteri.2020.05.003.</td>	480		doi:10.1016/j.arteri.2020.05.003.
 Health and Disease. <i>Nutrients</i> 12, (2020). Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448–2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 351, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Duble-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Ently High-Dose Vitamin D.30 for Critically Ill, Vitamin D-Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Ye, Z. <i>et al.</i> Association between circulating 25-hyd	481	4.	Charoenngam, N. & Holick, M. F. Immunologic Effects of Vitamin D on Human
 Marcos-Pérez, D. <i>et al.</i> Low Vitamin D Levels and Frailty Status in Older Adults: A Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian r	482		Health and Disease. Nutrients 12, (2020).
 Systematic Review and Meta-Analysis. <i>Nutrients</i> 12, (2020). Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. <i>Adv. Exp. Med. Biol.</i> 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? <i>Lancet Diabetes Endocrinol.</i> (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their cares (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D (3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016).	483	5.	Marcos-Pérez, D. et al. Low Vitamin D Levels and Frailty Status in Older Adults: A
 Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin D: A Review. Adv. Exp. Med. Biol. 1108, 13–23 (2018). Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol. (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. et al. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J. Med. Virol. (2020) doi:10.1002/jmv.26360. Rooney, M. R. et al. Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. JAMA 317, 2448– 2450 (2017). Manson, J. E. et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 380, 33–44 (2019). Pittas, A. G. et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 381, 520–530 (2019). Wactawski-Wende, J. et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354, 684–696 (2006). Sanders, K. M. et al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA 303, 1815–1822 (2010). Martineau, A. R. et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (VIDiFlu). Thorax 70, 953 LP – 960 (2015). Ginde, A. A. et al. Early High-Dose Vitamin D (2015). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018). Hysinger, E. B. et al. Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. J. Allergy Clin. Immunol. 138, 1747-1749.e4 (2016). Ye, Z. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabet	484		Systematic Review and Meta-Analysis, Nutrients 12, (2020).
 D: A Review. Adv. Exp. Med. Biol. 1108, 13–23 (2018). Mattineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol. (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. et al. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J. Med. Virol. (2020) doi:10.1002/jmv.26360. Rooney, M. R. et al. Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. JAMA 317, 2448– 2450 (2017). Manson, J. E. et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 380, 33–44 (2019). Pittas, A. G. et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 381, 520–530 (2019). Wactawski-Wende, J. et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354, 684–696 (2006). Sanders, K. M. et al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA 303, 1815–1822 (2010). Martineau, A. R. et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax 70, 953 LP – 960 (2015). Ginde, A. A. et al. Engl. J. Med. 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018). Hysinger, E. B. et al. Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. J. Allergy Clin. Immunol. 138, 1747-1749.e4 (2016). Ye, Z. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 3, 35–42 (2015). He, Y. et al. Exploring causality in the association between circulating 25- hydr	485	6.	Skrobot, A., Demkow, U. & Wachowska, M. Immunomodulatory Role of Vitamin
 Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol. (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. et al. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J. Med. Virol. (2020) doi:10.1002/jmv.26360. Rooney, M. R. et al. Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. JAMA 317, 2448– 2450 (2017). Manson, J. E. et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 380, 33–44 (2019). Pittas, A. G. et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 381, 520–530 (2019). Wactawski-Wende, J. et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354, 684–696 (2006). Sanders, K. M. et al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA 303, 1815–1822 (2010). Martineau, A. R. et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax 70, 953 LP – 960 (2015). Ginde, A. A. et al. Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Defricient Patients. N. Engl. J. Med. 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018). Hysinger, E. B. et al. Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. J. Allergy Clin. Immunol. 138, 1747-1749.e4 (2016). Ye, Z. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 3, 35–42 (2015). He, Y. e	486		D: A Review. Adv. Exp. Med. Biol. 1108 , 13–23 (2018).
 Lancet Diabetes Endocrinol. (2020) doi:10.1016/S2213-8587(20)30268-0. Munshi, R. et al. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J. Med. Virol. (2020) doi:10.1002/jmv.26360. Rooney, M. R. et al. Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. JAMA 317, 2448–2450 (2017). Manson, J. E. et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 380, 33–44 (2019). Pittas, A. G. et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 381, 520–530 (2019). Wactawski-Wende, J. et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354, 684–696 (2006). Sanders, K. M. et al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA 303, 1815–1822 (2010). Martineau, A. R. et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax 70, 953 LP – 960 (2015). Ginde, A. A. et al. Early High-Dose Vitamin D(3) for Critically III, Vitamin D-Deficient Patients. N. Engl. J. Med. 381, 5229–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018). Ye, Z. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 3, 35–42 (2015). He, Y. et al. Exploring causality in the association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 3, 35–42 (2015). He, Y. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mend	487	7.	Martineau, A. R. & Forouhi, N. G. Vitamin D for COVID-19: a case to answer?
 Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. <i>J. Med. Virol.</i> (2020) doi:10.1002/jmv.26360. Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y, <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a	488		Lancet Diabetes Endocrinol. (2020) doi:10.1016/S2213-8587(20)30268-0.
 patients. J. Med. Virol. (2020) doi:10.1002/jmv.26360. Rooney, M. R. et al. Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. JAMA 317, 2448– 2450 (2017). Manson, J. E. et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 380, 33–44 (2019). Pittas, A. G. et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N. Engl. J. Med. 381, 520–530 (2019). Wactawski-Wende, J. et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354, 684–696 (2006). Sanders, K. M. et al. Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. JAMA 303, 1815–1822 (2010). Martineau, A. R. et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax 70, 953 LP – 960 (2015). Ginde, A. A. et al. Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. N. Engl. J. Med. 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018). Hysinger, E. B. et al. Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. J. Allergy Clin. Immunol. 138, 1747-1749.e4 (2016). Ye, Z. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 3, 35-42 (2015). He, Y, et al. Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. BMC Med. 16, 142 (2018). Troingenice R. et al. Accompany to fe be capatio and elipiced determinents of 	489	8.	Munshi, R. <i>et al.</i> Vitamin D insufficiency as a potential culprit in critical COVID-19
 Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448– 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	490	•	patients, J. Med. Virol. (2020) doi:10.1002/imv.26360.
 Exceeding 1000 or 4000 International Units Daily, 1999-2014. <i>JAMA</i> 317, 2448–2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D-Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). Troinearde, K. <i>et al.</i> Accomperent of the constitution and elining determinents of study. <i>BMC Med.</i> 16, 142 (2018). 	491	9.	Rooney, M. R. <i>et al.</i> Trends in Use of High-Dose Vitamin D Supplements
 2450 (2017). Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	492	•	Exceeding 1000 or 4000 International Units Daily 1999-2014 JAMA 317 2448–
 Manson, J. E. <i>et al.</i> Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	493		2450 (2017)
 Cardiovascular Disease. <i>N. Engl. J. Med.</i> 380, 33–44 (2019). Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). Traipareneto, K. <i>et al.</i> Acagorament of the genetic and elinical determinents of 	494	10	Manson J. F. et al. Vitamin D. Supplements and Prevention of Cancer and
 Pittas, A. G. <i>et al.</i> Vitamin D Supplementation and Prevention of Type 2 Diabetes. <i>N. Engl. J. Med.</i> 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). Traipaneke, M. <i>et al.</i> Acapacement of the graphic and divised daterminente of 	495	10.	Cardiovascular Disease N Engl J Med 380 33–44 (2019)
 N. Engl. J. Med. 381, 520–530 (2019). Wactawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35-42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	496	11	Pittas A G et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes
 Watawski-Wende, J. <i>et al.</i> Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	497		N Engl J Med 381 520–530 (2019)
 of colorectal cancer. <i>N. Engl. J. Med.</i> 354, 684–696 (2006). Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). Trienzeke K. <i>et al.</i> Approximation of the agenetic and elipical determinants of the approximate of the agenetic and elipical determinants of the agenetic an	498	12	Wactawski-Wende, J. et al. Calcium plus vitamin D supplementation and the risk
 Sanders, K. M. <i>et al.</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	499		of colorectal cancer N Engl J Med 354 684–696 (2006)
 Ocher Women: A Randomized Controlled Trial. <i>JAMA</i> 303, 1815–1822 (2010). Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	500	13	Sanders K M <i>et al</i> Annual High-Dose Oral Vitamin D and Falls and Fractures in
 Martineau, A. R. <i>et al.</i> Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	500	10.	Older Women: A Randomized Controlled Trial JAMA 303 1815–1822 (2010)
 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	502	14	Martineau A R <i>et al</i> Double-blind randomised controlled trial of vitamin D3
 and their carers (ViDiFlu). <i>Thorax</i> 70, 953 LP – 960 (2015). Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	502		supplementation for the prevention of acute respiratory infection in older adults
 Ginde, A. A. <i>et al.</i> Early High-Dose Vitamin D(3) for Critically III, Vitamin D- Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	504		and their carers (ViDiFlu) Thorax 70 953 LP $=$ 960 (2015)
 Deficient Patients. <i>N. Engl. J. Med.</i> 381, 2529–2540 (2019). Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	505	15	Ginde A A et al Early High-Dose Vitamin D(3) for Critically III Vitamin D-
 Davies, N. M., Holmes, M. V & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	505	10.	Deficient Patients N Engl J Med 381 2529–2540 (2019)
 randomisation studies; a guide, glossary, and checklist for clinicians. <i>BMJ</i> 362, k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	500	16	Davies N.M. Holmes M.V.& Davey Smith G. Reading Mendelian
 k601 (2018). Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	508	10.	randomisation studies: a guide glossary and checklist for clinicians <i>BM1362</i>
 Hysinger, E. B. <i>et al.</i> Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. <i>J. Allergy Clin. Immunol.</i> 138, 1747-1749.e4 (2016). Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	500		
 11. Trysinger, L. B. et al. Mendenan randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. J. Allergy Clin. Immunol. 138, 1747-1749.e4 (2016). 18. Ye, Z. et al. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 3, 35–42 (2015). 19. He, Y. et al. Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. BMC Med. 16, 142 (2018). 20. Trainageke, K. et al. Association of the genetic and elipical determinants of 	510	17	Hysinger E B at al Mendelian randomization analysis demonstrates that low
 1747-1749.e4 (2016). 18. Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). 19. He, Y. <i>et al.</i> Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 20. Trainapako, K. <i>et al.</i> Associative for pediative distribution of the genetic and elipical determinants of the genetic and the ge	510	17.	vitamin D is unlikely causative for pediatric asthma / Alleray Clin Immunol 138
 Ye, Z. <i>et al.</i> Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). Trainpacko K. <i>et al.</i> Association of the genetic and elipical determinants of 	512		$1747-1749 ext{ } e$
 10. Te, 2. et al. Association between electrating 25 hydroxyvitamin <i>D</i> and incident type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes Endocrinol.</i> 3, 35–42 (2015). 19. He, Y. <i>et al.</i> Exploring causality in the association between circulating 25-hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 20. Trainageke, K. <i>et al.</i> Association between of the genetic and elipical determinants of the genetic and elipical determinan	512	18	Ye 7 et al. Association between circulating 25-bydroxywitamin D and incident
 study: Lancet Diabetes: a mendelian function study: Lancet Diabetes Endecimients, 5, 35–42 (2015). 19. He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). Trainpacko, K. <i>et al.</i> Association of the genetic and elipical determinants of the genetic and elipical determinants of the genetic and elipical determinants. 	517	10.	type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 3
 515 53-42 (2013). 516 19. He, Y. <i>et al.</i> Exploring causality in the association between circulating 25- 517 hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation 518 study. <i>BMC Med.</i> 16, 142 (2018). 519 20 	515		35_42 (2015)
 he, if et al. Exploring causality in the association between circulating 23- hydroxyvitamin D and colorectal cancer risk: a large Mendelian randomisation study. <i>BMC Med.</i> 16, 142 (2018). 	516	10	He V at a Exploring causality in the association between circulating 25 .
517 study. <i>BMC Med.</i> 16 , 142 (2018).	517	13.	hydroxyyitamin D and coloractal cancer risk: a large Mondolian randomisation
510 300 Trainnaka K at all Assassment of the constinued divised determinants of	512		study RMC Mod 16 142 (2018)
	510	20	Trajanoska K et al Assessment of the genetic and clinical determinants of
510 fracture risk: genome wide association and mendelian randomisation study RMI	520	20.	fracture risk: denome wide association and mendelian randomisation study RMI
521 362 , k3225 (2018).	521		362 , k3225 (2018).

522	21.	Despoina, M., E., M. L., Stephanie, R., David, G. & Brent, R. J. Mendelian
523		Randomization Studies Do Not Support a Role for Vitamin D in Coronary Artery
524		Disease. Circ. Cardiovasc. Genet. 9, 349–356 (2016).
525	22.	Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic
526		epidemiology contribute to understanding environmental determinants of
527		disease?*. Int. J. Epidemiol. 32, 1–22 (2003).
528	23.	Mokry, L. E. et al. Vitamin D and Risk of Multiple Sclerosis: A Mendelian
529		Randomization Study. PLOS Med. 12, e1001866 (2015).
530	24.	Manousaki, D. et al. Genome-wide Association Study for Vitamin D Levels
531		Reveals 69 Independent Loci. Am. J. Hum. Genet. 106, 327–337 (2020).
532	25.	Lawlor, D. A. Commentary: Two-sample Mendelian randomization: opportunities
533		and challenges. Int. J. Epidemiol. 45, 908–915 (2016).
534	26.	Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary
535		statistics identifies additional variants influencing complex traits. Nat. Genet. 44,
536		369-S3 (2012).
537	27.	Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring
538		population-specific haplotype structure and linking correlated alleles of possible
539		functional variants. Bioinformatics 31, 3555–3557 (2015).
540	28.	Initiative, T. C19 H. G. The COVID-19 Host Genetics Initiative, a global initiative
541		to elucidate the role of host genetic factors in susceptibility and severity of the
542		SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 28, 715–718 (2020).
543	29.	Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
544		genomewide association scans. <i>Bioinformatics</i> 26 , 2190–2191 (2010).
545	30.	Walker, V. M. et al. Using the MR-Base platform to investigate risk factors and
546		drug targets for thousands of phenotypes. Wellcome open Res. 4, 113 (2019).
547	31.	Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype
548		associations. Bioinformatics 32, 3207–3209 (2016).
549	32.	Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human
550		genotype-phenotype associations. <i>Bioinformatics</i> 35 , 4851–4853 (2019).
551	33.	Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic
552		data. <i>Nature</i> 562 , 203–209 (2018).
553	34.	Manousaki, D. et al. Low-Frequency Synonymous Coding Variation in CYP2R1
554		Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. Am. J.
555		Hum. Genet. 101 , 227–238 (2017).
556	35.	Astle, W. J. et al. The Allelic Landscape of Human Blood Cell Trait Variation and
557		Links to Common Complex Disease. Cell 167, 1415-1429.e19 (2016).
558	36.	Wuttke, M. et al. A catalog of genetic loci associated with kidney function from
559		analyses of a million individuals. Nat. Genet. 51, 957–972 (2019).
560	37.	Daneshkhah, A. et al. The Possible Role of Vitamin D in Suppressing Cytokine
561		Storm and Associated Mortality in COVID-19 Patients. medRxiv
562		2020.04.08.20058578 (2020) doi:10.1101/2020.04.08.20058578.
563	38.	Sinha, P., Matthay, M. A. & Calfee, C. S. Is a "Cytokine Storm" Relevant to
564		COVID-19? JAMA Intern. Med. (2020) doi:10.1001/jamainternmed.2020.3313.
565	39.	Aloia, J. F., Talwar, S. A., Pollack, S. & Yeh, J. A randomized controlled trial of
566		vitamin D3 supplementation in African American women. Arch. Intern. Med. 165,
567		1618–1623 (2005).
568	40.	Aspray, T. J. et al. Randomized controlled trial of vitamin D supplementation in
569		older people to optimize bone health. Am. J. Clin. Nutr. 109, 207–217 (2019).
570	41.	Preventing COVID-19 With High-dose Vitamin D Supplements.
571		https://clinicaltrials.gov/show/NCT04483635.
572	42.	Cholecalciferol to Improve the Outcomes of COVID-19 Patients.

- 573 https://clinicaltrials.gov/show/NCT04411446.
- 43. Hastie, C. E. *et al.* Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab. Syndr.* **14**, 561–565 (2020).
- 44. Hastie, C. E., Pell, J. P. & Sattar, N. Short Communication: Vitamin D and COVID19 infection and mortality in UK Biobank. *medRxiv* 2020.06.26.20140921 (2020)
 doi:10.1101/2020.06.26.20140921.

579

Phenotype	Source of genetic variants			
	Cohort	Participants		
25OHD circulating levels	Manousaki <i>et al²⁴</i>	Meta-analysis of two 250HD GWAS:		
		- 401,460 adult white British participants form the UKB ³³		
		- 42,274 from an international consortium of adult individuals of European ancestry		
Covid-19 susceptibility	Susceptibility	Meta-analysis of 6 GWAS performed in individuals of European ancestry from 4 countries:		
		- Cases: 3,432 individuals with Covid-19 by laboratory confirmation, chart review, or self-		
		report		
		 Controls: 41,285 individuals without Covid-19 by laboratory confirmation or self-report 		
Covid-19 severity	Hospitalized	Meta-analysis of 3 GWAS performed in individuals of European ancestry from 3 countries:		
		Cases: 867 hospitalized individuals with Covid-19		
		Controls: 2,229 non-hospitalized individuals with Covid-19		
	Severe Disease	GWAS from white British UKB participants:		
		- Cases: 293 Covid-19 infected hospitalized individuals who died or required respiratory		
		support (intubation, CPAP, BiPAP, continuous external negative pressure, high flow		
		nasal cannula).		
		- Controls: 607 non-hospitalized individuals with Covid-19		

Table 1: Sources of data for the analysis. Covid-19 susceptibility and severity outcomes are taken from the Covid-19 HGI²⁸. See Supplement 1 for details on cohorts of Covid-19 susceptibility and severity phenotypes.

Outcome	nSNPs	IVW OR (95% CI)	IVW p-value	Egger alpha	Alpha p-value	Egger OR (95% CI)	Egger p-value			
25OHD primary analysis										
Susceptibility	96	0.88 (0.69, 1.11)	0.26	0.005 (-0.006, 0.02)	0.39	0.79 (0.57, 1.10)	0.16			
Hospitalization	95	2.34 (1.33, 4.11)	0.003	-0.005 (-0.03, 0.02)	0.70	2.61 (1.18, 5.78)	0.02			
Severe disease	96	2.21 (0.88, 5.55)	0.09	-0.03 (-0.07, 0.02)	0.27	3.78 (1.01, 14.1)	0.05			
250HD sensitivity analysis restricted to genes in the vitamin D pathway										
Susceptibility	21	0.90 (0.64, 1.27)	0.55	0.04 (-0.0001, 0.08)	0.07	0.61 (0.37, 1.01)	0.07			
Hospitalization	21	2.52 (1.28, 4.95)	0.007	0.02 (-0.06, 0.11)	0.58	1.97 (0.66, 5.84)	0.24			
Severe disease	21	3.04 (1.06, 8.76)	0.04	-0.09 (-0.21, 0.04)	0.20	7.68 (1.35, 43.5)	0.03			
250HD sensitivity analysis after removal of SNPs identified by Phenoscanner										
Susceptibility	19	0.77 (0.48, 1.23)	0.27	0.06 (0.01, 0.10)	0.02	0.38 (0.19, 0.75)	0.01			
Hospitalization	19	2.89 (1.18, 7.06)	0.02	0.0005 (-0.10, 0.10)	0.99	2.87 (0.64, 12.9)	0.19			
Severe disease	19	2.52 (0.63, 10.0)	0.19	-0.14 (-0.29, 0.006)	0.08	17.1 (1.50, 195)	0.04			

 Table 2: MR results. nSNPs: number of SNPs retained for this analysis. CI: confidence interval.



Figure 1: Vitamin D synthesis pathway.



Figure 2: Odds ratio point estimates and 95% confidence intervals for a one standard deviation increase in 25OHD levels on Covid-19 susceptibility and severity. Restricted: analysis restricted to SNPs near the 4 genes involved in known vitamin D metabolic pathways. Restricted-Phenoscanner: restricted analysis, with SNPs identified to have other associations in Phenoscanner removed.